Despite the fact that it belongs to the most potent anti-inflammatory cytokine, limited efficacy with subcutaneously administered recombinant IL-10 was observed in a phase I trial in patients with RA in the past40. The gene discussed is IL10; the disease is rheumatoid arthritis.